EP1436329A4 - ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES - Google Patents
ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIESInfo
- Publication number
- EP1436329A4 EP1436329A4 EP02775937A EP02775937A EP1436329A4 EP 1436329 A4 EP1436329 A4 EP 1436329A4 EP 02775937 A EP02775937 A EP 02775937A EP 02775937 A EP02775937 A EP 02775937A EP 1436329 A4 EP1436329 A4 EP 1436329A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- methods
- pdgf
- producing engineered
- engineered antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32354401P | 2001-09-20 | 2001-09-20 | |
| US32353701P | 2001-09-20 | 2001-09-20 | |
| US323537P | 2001-09-20 | ||
| US323544P | 2001-09-20 | ||
| US37999402P | 2002-05-13 | 2002-05-13 | |
| US379994P | 2002-05-13 | ||
| PCT/US2002/030086 WO2003025019A1 (en) | 2001-09-20 | 2002-09-20 | Anti-pdgf antibodies and methods for producing engineered antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1436329A1 EP1436329A1 (en) | 2004-07-14 |
| EP1436329A4 true EP1436329A4 (en) | 2005-04-27 |
Family
ID=27406282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02775937A Withdrawn EP1436329A4 (en) | 2001-09-20 | 2002-09-20 | ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1436329A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005512962A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2460587A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003025019A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| JP4723810B2 (ja) | 2001-12-03 | 2011-07-13 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ハイブリッド抗体 |
| AU2003213022A1 (en) * | 2002-02-11 | 2003-09-22 | Alexion Pharmaceuticals, Inc. | Immunotherapeutics for biodefense |
| NZ542988A (en) * | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
| JO3787B1 (ar) | 2012-03-15 | 2021-01-31 | Janssen Biotech Inc | أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| SG11201408196RA (en) * | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| WO2014052518A1 (en) | 2012-09-27 | 2014-04-03 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
| CN105188759A (zh) | 2013-03-14 | 2015-12-23 | 阿勒根公司 | 持续释放递送的组合物以及在制造过程中稳定蛋白质的方法 |
| SI4374873T1 (sl) | 2013-07-12 | 2026-01-30 | Astellas Us Llc | Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj |
| JP2019006732A (ja) * | 2017-06-27 | 2019-01-17 | 学校法人東京理科大学 | Mycタンパク質阻害剤、Mycタンパク質阻害方法、抗神経芽腫剤及びMycタンパク質の過剰発現を伴う疾患の治療方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024059A1 (en) * | 1997-11-07 | 1999-05-20 | Massachusetts Institute Of Technology | Pdgf-mediated microvascular communication and methods of use thereof |
| WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6180370B1 (en) * | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5976534A (en) * | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
-
2002
- 2002-09-20 JP JP2003528864A patent/JP2005512962A/ja not_active Withdrawn
- 2002-09-20 EP EP02775937A patent/EP1436329A4/en not_active Withdrawn
- 2002-09-20 WO PCT/US2002/030086 patent/WO2003025019A1/en not_active Ceased
- 2002-09-20 CA CA002460587A patent/CA2460587A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180370B1 (en) * | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
| WO1999024059A1 (en) * | 1997-11-07 | 1999-05-20 | Massachusetts Institute Of Technology | Pdgf-mediated microvascular communication and methods of use thereof |
| WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
Non-Patent Citations (5)
| Title |
|---|
| BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES. 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205 * |
| CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 * |
| See also references of WO03025019A1 * |
| SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050 * |
| WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2460587A1 (en) | 2003-03-27 |
| WO2003025019A9 (en) | 2004-05-06 |
| JP2005512962A (ja) | 2005-05-12 |
| WO2003025019A8 (en) | 2004-04-01 |
| WO2003025019A1 (en) | 2003-03-27 |
| EP1436329A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1432444A4 (en) | ANTI-BETA ANTIBODIES | |
| PT1406656E (pt) | Métodos para administração de anticorpos anti-tnfα | |
| AU2002346641A8 (en) | Apertured non-woven composites and method for making | |
| IL157142A0 (en) | Modified antibodies and methods of use | |
| HUP0402333A3 (en) | Modified anti-tnf alpha antibody | |
| AU4002001A (en) | High potency recombinant antibodies and method for producing them | |
| PT1361893E (pt) | Anticorpos anti-rfce modificados com imunogenicidade reduzida | |
| TWI346203B (en) | Antibody pair screening methods | |
| EP1494693A4 (en) | SPECIFIC ANTIBODIES TO CRIPTO | |
| GB0128287D0 (en) | Novel method and compounds | |
| EP1585501A4 (en) | PREPARATIONS OF DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF | |
| AU2002365649A8 (en) | Anti-dota antibody | |
| GB2387599B (en) | Methods for producing antibodies | |
| AU2002367943A8 (en) | Improved reagents and methods for producing parvoviruses | |
| AU2002359495A8 (en) | Anti-tnf antibodies, compositions, methods and uses | |
| AU2003213718A8 (en) | Method of producing antigens | |
| GB0111004D0 (en) | Screening method | |
| PL374439A1 (en) | Antibodies and uses thereof | |
| GB0221940D0 (en) | Antibody and screening method | |
| TWI318239B (en) | Methods for producing novel medaka and novel medaka | |
| GB0119553D0 (en) | Antibodies | |
| AU2002307968A1 (en) | Method for preparing and selecting antibodies | |
| GB0118696D0 (en) | Novel antibodies | |
| GB0119004D0 (en) | Antibody | |
| GB0108975D0 (en) | Novel method and compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040316 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20050308 |
|
| 17Q | First examination report despatched |
Effective date: 20050808 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20071219 |